Gemini Therapeutics (GMTX) Competitors $47.13 +2.31 (+5.15%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesInsider TradesSEC FilingsTrends GMTX vs. VKTX, LEGN, ASND, LNTH, ELAN, CYTK, NUVL, BPMC, KRYS, and BHVNShould you be buying Gemini Therapeutics stock or one of its competitors? The main competitors of Gemini Therapeutics include Viking Therapeutics (VKTX), Legend Biotech (LEGN), Ascendis Pharma A/S (ASND), Lantheus (LNTH), Elanco Animal Health (ELAN), Cytokinetics (CYTK), Nuvalent (NUVL), Blueprint Medicines (BPMC), Krystal Biotech (KRYS), and Biohaven (BHVN). These companies are all part of the "pharmaceutical products" industry. Gemini Therapeutics vs. Viking Therapeutics Legend Biotech Ascendis Pharma A/S Lantheus Elanco Animal Health Cytokinetics Nuvalent Blueprint Medicines Krystal Biotech Biohaven Viking Therapeutics (NASDAQ:VKTX) and Gemini Therapeutics (NASDAQ:GMTX) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, community ranking, earnings, valuation and profitability. Does the MarketBeat Community prefer VKTX or GMTX? Viking Therapeutics received 593 more outperform votes than Gemini Therapeutics when rated by MarketBeat users. Likewise, 79.69% of users gave Viking Therapeutics an outperform vote while only 63.33% of users gave Gemini Therapeutics an outperform vote. CompanyUnderperformOutperformViking TherapeuticsOutperform Votes61279.69% Underperform Votes15620.31% Gemini TherapeuticsOutperform Votes1963.33% Underperform Votes1136.67% Do institutionals & insiders have more ownership in VKTX or GMTX? 76.0% of Viking Therapeutics shares are held by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are held by institutional investors. 4.7% of Viking Therapeutics shares are held by company insiders. Comparatively, 12.9% of Gemini Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is VKTX or GMTX more profitable? Viking Therapeutics' return on equity of -12.73% beat Gemini Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Viking TherapeuticsN/A -12.73% -12.31% Gemini Therapeutics N/A -38.78%-35.88% Do analysts rate VKTX or GMTX? Viking Therapeutics presently has a consensus price target of $108.60, suggesting a potential upside of 49.01%. Given Viking Therapeutics' higher probable upside, analysts clearly believe Viking Therapeutics is more favorable than Gemini Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viking Therapeutics 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Which has more volatility and risk, VKTX or GMTX? Viking Therapeutics has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.Comparatively, Gemini Therapeutics has a beta of -0.12, indicating that its share price is 112% less volatile than the S&P 500. Does the media prefer VKTX or GMTX? In the previous week, Viking Therapeutics had 31 more articles in the media than Gemini Therapeutics. MarketBeat recorded 31 mentions for Viking Therapeutics and 0 mentions for Gemini Therapeutics. Viking Therapeutics' average media sentiment score of 0.27 beat Gemini Therapeutics' score of 0.00 indicating that Viking Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Viking Therapeutics Neutral Gemini Therapeutics Neutral Which has higher valuation and earnings, VKTX or GMTX? Viking Therapeutics is trading at a lower price-to-earnings ratio than Gemini Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioViking TherapeuticsN/AN/A-$85.89M-$0.93-78.36Gemini TherapeuticsN/AN/A-$71.87M-$1.00-47.13 SummaryViking Therapeutics beats Gemini Therapeutics on 12 of the 15 factors compared between the two stocks. Ad Paradigm PressEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… Get Gemini Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GMTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GMTX vs. The Competition Export to ExcelMetricGemini TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.04B$7.42B$5.54B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio-47.139.93114.8115.14Price / SalesN/A396.631,495.55100.10Price / CashN/A47.3939.6734.08Price / Book16.315.324.665.02Net Income-$71.87M$153.56M$119.06M$225.46M7 Day Performance2.43%0.13%0.80%0.37%1 Month Performance-7.95%15.23%5.65%3.57%1 Year Performance2.48%41.14%36.75%29.43% Gemini Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GMTXGemini TherapeuticsN/A$47.13+5.2%N/A+2.9%$2.04BN/A-47.1330VKTXViking Therapeutics4.1533 of 5 stars$72.88+0.5%$108.60+49.0%+661.5%$8.12BN/A-78.3620LEGNLegend Biotech2.0701 of 5 stars$44.36-1.5%$82.08+85.0%-33.6%$8.09B$285.14M-56.871,800Analyst ForecastASNDAscendis Pharma A/S3.0734 of 5 stars$125.28+2.0%$195.92+56.4%+38.0%$7.60B$288.08M-13.46640Upcoming EarningsLNTHLantheus4.3953 of 5 stars$107.98-1.7%$126.00+16.7%+63.4%$7.50B$1.30B17.70834Upcoming EarningsNews CoveragePositive NewsELANElanco Animal Health4.1919 of 5 stars$12.59-0.4%$17.00+35.0%+45.7%$6.22B$4.42B-4.949,300Upcoming EarningsShort Interest ↓CYTKCytokinetics4.2687 of 5 stars$51.82+1.6%$83.93+62.0%+47.6%$6.10B$7.53M-9.65250Upcoming EarningsInsider SellingShort Interest ↓NUVLNuvalent3.2819 of 5 stars$89.22+0.8%$112.40+26.0%+66.2%$5.78BN/A-32.0940Insider SellingBPMCBlueprint Medicines2.218 of 5 stars$90.70+3.6%$120.39+32.7%+51.4%$5.75B$434.42M-42.99640Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageKRYSKrystal Biotech4.6421 of 5 stars$176.39+2.2%$196.75+11.5%+47.8%$5.07B$166.23M48.33229Upcoming EarningsBHVNBiohaven2.6559 of 5 stars$50.86+2.2%$61.92+21.7%+72.5%$4.81B$462.51M-5.56239 Related Companies and Tools Related Companies Viking Therapeutics Alternatives Legend Biotech Alternatives Ascendis Pharma A/S Alternatives Lantheus Alternatives Elanco Animal Health Alternatives Cytokinetics Alternatives Nuvalent Alternatives Blueprint Medicines Alternatives Krystal Biotech Alternatives Biohaven Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GMTX) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gemini Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gemini Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GMTX Stock Alerts